Targeting neutrophils potentiates hitchhiking delivery of drugs and agonists for postsurgical chemo-immunotherapy
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Immune cells in cancer · Immunotherapy and Immune Responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (60)
Show source-provided references
1. Nanotechnology for multimodal synergistic cancer therapy10.1021/acs.chemrev.7b00258 ↗
2. Cancer nanomedicine: progress, challenges and opportunities10.1038/nrc.2016.108 ↗
3. Minimal Dosing of Leukocyte Targeting TRAIL Decreases Triple-negative Breast Cancer Metastasis Following Tumor Resection10.1126/sciadv.aaw4197 ↗
4. Red Blood Cell-Facilitated Photodynamic Therapy for Cancer Treatment10.1002/adfm.201504803 ↗
5. Sono-Polymerization of Poly(ethylene glycol)-Based Nanoparticles for Targeted Drug Delivery10.1021/acsmacrolett.9b00576 ↗
6. Neutrophil-Mediated Anticancer Drug Delivery for Suppression of Postoperative Malignant Glioma Recurrence,10.1038/nnano.2017.54 ↗
7. Neutrophil-like Cell-Membrane-Coated Nanozyme Therapy for Ischemic Brain Damage and Long-Term Neurological Functional Recovery10.1021/acsnano.0c07973 ↗
8. In vivo Hitchhiking of Immune Cells by Intracellular Self-assembly of Bacteria-Mimetic Nanomedicine for Targeted Therapy of Melanoma,10.1126/sciadv.abn1805 ↗
9. Neutrophil Decoys with Anti-Inflammatory and Anti‐Oxidative Properties Reduce Secondary Spinal Cord Injury and Improve Neurological Functional Recovery10.1002/adfm.202102912 ↗
10. Cellular Backpacks for Macrophage Immunotherapy
11. Neutrophil-Membrane-Directed Bioorthogonal Synthesis of Inflammation-Targeting Chiral Drugs10.1016/j.chempr.2020.06.002 ↗
12. Neutrophil Cyto-Pharmaceuticals Suppressing Tumor Metastasis via Inhibiting Hypoxia-Inducible Factor-1alpha in Circulating Breast Cancer Cells10.1002/adhm.202101761 ↗
13. Cell-Based Delivery Systems: Emerging Carriers for Immunotherapy.
14. Multistage Targeted “Photoactive Neutrophil” for Enhancing Synergistic Photo-Chemotherapy10.1016/j.biomaterials.2021.121224 ↗
15. Neoadjuvant Chemotherapy Based on Abraxane/Human Neutrophils Cytopharmaceuticals with Radiotherapy for Gastric Cancer10.1002/smll.201804191 ↗
16. Chemotaxis-Driven Delivery of Nano-Pathogenoids for Complete Eradication of Tumors Post-Phototherapy
17. Targeting Neutrophils for Enhanced Cancer Theranostic10.1002/adma.202002739 ↗
18. Neutrophil-Based Drug Delivery Systems10.1002/adma.201706245 ↗
19. Trojan Horse" Salmonella Enabling Tumor Homing of Silver Nanoparticles via Neutrophil Infiltration for Synergistic Tumor Therapy and Enhanced Biosafety10.1021/acs.nanolett.0c03811 ↗
20. Photosensitization Priming of Tumor Microenvironments Improves Delivery of Nanotherapeutics via Neutrophil Infiltration,10.1002/adma.201701021 ↗
21. Engineered Drug-loaded Cellular Membrane Nanovesicles for Efficient Treatment of Postsurgical Cancer Recurrence and Metastasis,10.1126/sciadv.add3599 ↗
22. Nanodelivery of Immunogenic Cell Death-inducers for Cancer Immunotherapy10.1016/j.drudis.2020.11.029 ↗
23. Phototheranostic Metal-Phenolic Networks with Antiexosomal PD-L1 Enhanced Ferroptosis for Synergistic Immunotherapy10.1021/jacs.1c09753 ↗
24. Multifunctional Oncolytic Nanoparticles Deliver Self-replicating IL-12 RNA to Eliminate Established Tumors and Prime Systemic Immunity10.1038/s43018-020-0095-6 ↗
25. Targeting Photodynamic and Photothermal Therapy to the Endoplasmic Reticulum Enhances Immunogenic Cancer Cell Death
26. Immunogenic cell death in cancer therapy10.1146/annurev-immunol-032712-100008 ↗
27. Manganese-Phenolic Nanoadjuvant Combines Sonodynamic Therapy with cGAS-STING Activation for Enhanced Cancer Immunotherapy10.1016/j.nantod.2022.101405 ↗
28. Engineering Radiosensitizer-Based Metal-Phenolic Networks Potentiate STING Pathway Activation for Advanced Radiotherapy10.1002/adma.202105783 ↗
29. Synthetic Immunogenic Cell Death Mediated by Intracellular Delivery of STING Agonist Nanoshells Enhances Anticancer Chemo-immunotherapy10.1021/acs.nanolett.9b04094 ↗
30. Biomineralized MnO2 Nanoplatforms Mediated Delivery of Immune Checkpoint Inhibitors with STING Pathway Activation to Potentiate Cancer Radio-Immunotherapy10.1021/acsnano.2c10352 ↗
31. Bioinspired magnetic nanocomplexes amplifying STING activation of tumor-associated macrophages to potentiate cancer immunotherapy10.1016/j.nantod.2022.101400 ↗
32. Considerations for Designing Preclinical Cancer Immune Nanomedicine Studies10.1038/s41565-020-00817-9 ↗
33. Supramolecular Assembled Programmable Nanomedicine As In Situ Cancer Vaccine for Cancer Immunotherapy
34. Nanoparticle-Enhanced Radiotherapy to Trigger Robust Cancer Immunotherapy
35. Immunogenic Cell Death in Hematological Malignancy Therapy
36. Nitric Oxide Induces Immunogenic Cell Death and Potentiates Cancer Immunotherapy10.1021/acsnano.1c09048 ↗
37. The Cyclopeptide Astin C Specifically Inhibits the Innate Immune CDN Sensor STING,10.1016/j.celrep.2018.11.097 ↗
38. A Cyclic Dinucleotide Containing 2-Aminopurine is A General Fluorescent Sensor for c-di-GMP and 3′,3′-cGAMP10.1039/C3MB70518H ↗
39. c-di-AMP Secreted by Intracellular Listeria Monocytogenes Activates a Host Type I Interferon Response10.1126/science.1189801 ↗
40. Cyclic GMP-AMP Synthase is a Cytosolic DNA Sensor that Activates the Type I Interferon Pathway10.1126/science.1232458 ↗
41. Endosomolytic Polymersomes Increase the Activity of Cyclic Dinucleotide STING Agonists to Enhance Cancer Immunotherapy10.1038/s41565-018-0342-5 ↗
42. An Orally Available Non-Nucleotide STING Agonist with Antitumor Activity10.1126/science.aba6098 ↗
43. Antitumor Activity of a Systemic STING-Activating Non-Nucleotide cGAMP Mimetic10.1126/science.abb4255 ↗
44. Engineering Poly(ethylene glycol) Nanoparticles for Accelerated Blood Clearance Inhibition and Targeted Drug Delivery10.1021/jacs.2c06877 ↗
45. IFI16 Promotes Cervical Cancer Progression by Upregulating PD-L1 in Immunomicroenvironment Through STING-TBK1-NF-kB Pathway10.1016/j.biopha.2019.109790 ↗
46. Fibronectin-Coated Metal-Phenolic Networks for Cooperative Tumor Chemo-/Chemodynamic/Immune Therapy via Enhanced Ferroptosis-Mediated Immunogenic Cell Death10.1021/acsnano.1c08585 ↗
47. Carrier-Free Nanoassembly of Doxorubicin Prodrug and siRNA for Combinationally Inducing Immunogenic Cell Death and Reversing Immunosuppression10.1016/j.nantod.2020.100924 ↗
48. Trident Molecule with Nanobrush–Nanoparticle–Nanofiber Transition Property Spatially Suppresses Tumor Metastasis10.1021/jacs.2c05743 ↗
49. Targeted Delivery of a STING Agonist to Brain Tumors Using Bioengineered Protein Nanoparticles for Enhanced Immunotherapy,
50. A Polyvalent Peptide CD40 Nanoagonist for Targeted Modulation of Dendritic Cells and Amplified Cancer Immunotherapy10.1002/adma.202109432 ↗
51. Strategies targeting tumor immune and stromal microenvironment and their clinical relevance10.1016/j.addr.2022.114137 ↗
52. Epigenetic Modulation of Antitumor Immunity for Improved Cancer Immunotherapy10.1186/s12943-021-01464-x ↗
53. Toxicity of Doxorubicin (Dox) to Different Experimental Organ Systems10.1016/j.lfs.2018.03.023 ↗
54. Alleviation of the Doxorubicin-induced Nephrotoxicity by Fasudil in vivo and in vitro10.1016/j.jphs.2020.10.002 ↗
55. Antigen Presentation in Cancer: Insights into Tumour Immunogenicity and Immune Evasion10.1038/s41568-021-00339-z ↗
56. Accelerating Thrombolysis Using a Precision and Clot-penetrating Drug Delivery Strategy by Nanoparticle-Shelled Microbubbles
57. Enhanced Tumour Penetration and Prolonged Circulation in Blood of Polyzwitterion-Drug Conjugates with Cell-Membrane Affinity10.1038/s41551-021-00701-4 ↗
58. Stimuli-Responsive Clustered Nanoparticles for Improved Tumor Penetration and Therapeutic Efficacy10.1073/pnas.1522080113 ↗
59. Neoadjuvant Therapy with Immune Checkpoint Blockade, Antiangiogenesis, and Chemotherapy for Locally Advanced Gastric Cancer
60. Nanodrug Shows Spatiotemporally Controlled Release of Anti-PD-L1 Antibody and STING Agonist to Effectively Inhibit Tumor Progression After Radiofrequency Ablation10.1016/j.nantod.2022.101425 ↗